Abstract

The amyloid‐β (Aβ) cascade hypothesis of Alzheimer’s disease (AD) holds that brain accumulation of Aβ initiates the disease process. Accordingly, drug research has targeted Aβ production, clearance or deposition as therapeutic strategies. Unfortunately, candidate drugs have failed to show clinical benefit in established, early or prodromal disease, or those with high AD risk. Currently, monoclonal antibodies specifically directed against the most neurotoxic Aβ forms are undergoing large scale trials to confirm initially encouraging results. However, recent findings on the normal physiology of Aβ suggest that accumulation may be compensatory rather than the pathological initiator. If this is true, alternative strategies will be needed to defeat this devastating disease.

This article is protected by copyright. All rights reserved.

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...